CN103328649B - 用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列 - Google Patents
用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列 Download PDFInfo
- Publication number
- CN103328649B CN103328649B CN201180065369.5A CN201180065369A CN103328649B CN 103328649 B CN103328649 B CN 103328649B CN 201180065369 A CN201180065369 A CN 201180065369A CN 103328649 B CN103328649 B CN 103328649B
- Authority
- CN
- China
- Prior art keywords
- signal sequence
- protein
- bip
- polypeptide
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41592610P | 2010-11-22 | 2010-11-22 | |
| US61/415,926 | 2010-11-22 | ||
| PCT/US2011/061862 WO2012071422A2 (en) | 2010-11-22 | 2011-11-22 | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103328649A CN103328649A (zh) | 2013-09-25 |
| CN103328649B true CN103328649B (zh) | 2016-06-22 |
Family
ID=46146394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180065369.5A Active CN103328649B (zh) | 2010-11-22 | 2011-11-22 | 用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9279007B2 (enExample) |
| EP (2) | EP3461905B1 (enExample) |
| JP (1) | JP2014503198A (enExample) |
| KR (2) | KR101984318B1 (enExample) |
| CN (1) | CN103328649B (enExample) |
| BR (1) | BR112013012671B1 (enExample) |
| CA (1) | CA2818689C (enExample) |
| CY (1) | CY1121049T1 (enExample) |
| DK (2) | DK3461905T3 (enExample) |
| ES (2) | ES2687415T3 (enExample) |
| HR (1) | HRP20181315T1 (enExample) |
| HU (1) | HUE039070T2 (enExample) |
| LT (1) | LT2643468T (enExample) |
| PL (1) | PL2643468T3 (enExample) |
| PT (1) | PT2643468T (enExample) |
| RS (1) | RS57601B1 (enExample) |
| SI (1) | SI2643468T1 (enExample) |
| SM (1) | SMT201800466T1 (enExample) |
| WO (1) | WO2012071422A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20192243T1 (hr) | 2014-07-03 | 2020-03-06 | F. Hoffmann - La Roche Ag | Polipeptidni ekspresijski sustavi |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN110809583A (zh) | 2017-06-07 | 2020-02-18 | 瑞泽恩制药公司 | 用于内化酶的组合物和方法 |
| TW201927825A (zh) * | 2017-11-30 | 2019-07-16 | 美商阿米庫斯醫療股份有限公司 | Cdkl5 表現變體和cdkl5 融合蛋白 |
| KR20200118151A (ko) | 2018-02-07 | 2020-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 치료 단백질 전달을 위한 방법 및 조성물 |
| BR112020021962A2 (pt) * | 2018-04-30 | 2021-01-26 | Amicus Therapeutics, Inc. | construtos para terapia gênica e métodos de uso |
| MX2020012350A (es) | 2018-05-17 | 2021-01-29 | Regeneron Pharma | Anticuerpos anti-cd63, conjugados y usos de estos. |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3863663A2 (en) | 2018-10-10 | 2021-08-18 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| KR20210105382A (ko) * | 2018-12-19 | 2021-08-26 | 베르사멥 아게 | 단백질을 코딩하는 rna |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| BR112021021720A2 (pt) * | 2019-04-30 | 2021-12-28 | Univ Pennsylvania | Composições úteis para tratamento de doença de pompe |
| EP3983538A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN112342247B (zh) * | 2020-11-10 | 2022-03-11 | 江苏科技大学 | 一种提高家蚕细胞表达外源蛋白分泌率的方法 |
| CA3200192A1 (en) | 2020-12-01 | 2022-06-09 | Justin PERCIVAL | Compositions and uses thereof for treatment of angelman syndrome |
| US20250034533A1 (en) | 2021-11-12 | 2025-01-30 | Amicus Therapeutics, Inc. | Compositions And Methods For Treating Mucopolysaccharidosis IIIA |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2352286C (en) * | 1998-11-24 | 2011-07-12 | Bristol-Myers Squibb Company | Intracellular targeted delivery of compounds by 70 kd heat shock protein |
| US7279564B2 (en) * | 2003-11-06 | 2007-10-09 | Genencor International, Inc. | Expression in filamentous fungi of protease inhibitors and variants thereof |
| DE602007007923D1 (de) * | 2006-04-11 | 2010-09-02 | Csl Behring Gmbh | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide |
-
2011
- 2011-11-22 EP EP18181451.8A patent/EP3461905B1/en active Active
- 2011-11-22 ES ES11843849.8T patent/ES2687415T3/es active Active
- 2011-11-22 ES ES18181451T patent/ES2829199T3/es active Active
- 2011-11-22 SM SM20180466T patent/SMT201800466T1/it unknown
- 2011-11-22 HR HRP20181315TT patent/HRP20181315T1/hr unknown
- 2011-11-22 EP EP11843849.8A patent/EP2643468B1/en active Active
- 2011-11-22 PT PT11843849T patent/PT2643468T/pt unknown
- 2011-11-22 BR BR112013012671-0A patent/BR112013012671B1/pt not_active IP Right Cessation
- 2011-11-22 DK DK18181451.8T patent/DK3461905T3/da active
- 2011-11-22 SI SI201131554T patent/SI2643468T1/sl unknown
- 2011-11-22 RS RS20180986A patent/RS57601B1/sr unknown
- 2011-11-22 CA CA2818689A patent/CA2818689C/en active Active
- 2011-11-22 CN CN201180065369.5A patent/CN103328649B/zh active Active
- 2011-11-22 JP JP2013541026A patent/JP2014503198A/ja not_active Withdrawn
- 2011-11-22 DK DK11843849.8T patent/DK2643468T3/en active
- 2011-11-22 KR KR1020137016110A patent/KR101984318B1/ko active Active
- 2011-11-22 PL PL11843849T patent/PL2643468T3/pl unknown
- 2011-11-22 HU HUE11843849A patent/HUE039070T2/hu unknown
- 2011-11-22 WO PCT/US2011/061862 patent/WO2012071422A2/en not_active Ceased
- 2011-11-22 KR KR1020197015057A patent/KR20190060888A/ko not_active Ceased
- 2011-11-22 LT LTEP11843849.8T patent/LT2643468T/lt unknown
- 2011-11-22 US US13/988,946 patent/US9279007B2/en active Active
-
2018
- 2018-09-12 CY CY181100941T patent/CY1121049T1/el unknown
Non-Patent Citations (3)
| Title |
|---|
| Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (Bip) and inhibits its ATPase activity in human fibroblasts;Deng 等;《FASEB J》;20011130;第15卷(第13期);第2463-2470页 * |
| Targeting to the endoplasmic reticulum improves the folding of recombinant human telomerase reverse transcriptase;Wu等;《Protein Expr.purif》;20071130;第56卷(第1期);第8-19页 * |
| 分子伴侣与MHC分子;吴涓涓;《国外医学(免疫学分册)》;20041105;第27卷(第6期);第358-361页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013012671A2 (pt) | 2016-10-11 |
| KR101984318B1 (ko) | 2019-05-31 |
| WO2012071422A3 (en) | 2012-08-02 |
| CA2818689C (en) | 2021-09-21 |
| PT2643468T (pt) | 2018-10-11 |
| BR112013012671B1 (pt) | 2022-03-03 |
| HUE039070T2 (hu) | 2018-12-28 |
| CY1121049T1 (el) | 2019-12-11 |
| DK2643468T3 (en) | 2018-09-24 |
| EP2643468A2 (en) | 2013-10-02 |
| EP2643468B1 (en) | 2018-07-04 |
| ES2829199T3 (es) | 2021-05-31 |
| ES2687415T3 (es) | 2018-10-25 |
| PL2643468T3 (pl) | 2018-11-30 |
| LT2643468T (lt) | 2018-09-10 |
| KR20190060888A (ko) | 2019-06-03 |
| KR20130121878A (ko) | 2013-11-06 |
| JP2014503198A (ja) | 2014-02-13 |
| HRP20181315T1 (hr) | 2018-10-19 |
| EP3461905A1 (en) | 2019-04-03 |
| US20140045216A1 (en) | 2014-02-13 |
| EP2643468A4 (en) | 2014-12-24 |
| EP3461905B1 (en) | 2020-08-05 |
| CN103328649A (zh) | 2013-09-25 |
| DK3461905T3 (da) | 2020-11-02 |
| WO2012071422A2 (en) | 2012-05-31 |
| CA2818689A1 (en) | 2012-05-31 |
| US9279007B2 (en) | 2016-03-08 |
| SMT201800466T1 (it) | 2018-11-09 |
| RS57601B1 (sr) | 2018-11-30 |
| SI2643468T1 (sl) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103328649B (zh) | 用于改善重组酶及其它蛋白的蛋白表达和分泌的新的信号序列 | |
| JPH02167095A (ja) | 異種蛋白質の製造方法、組換えｄｎａ、形質転換体 | |
| Dou et al. | Type II transmembrane domain hydrophobicity dictates the cotranslational dependence for inversion | |
| Bae et al. | A novel fusion partner for enhanced secretion of recombinant proteins in Saccharomyces cerevisiae | |
| CN110760541B (zh) | 用中国仓鼠卵巢细胞表达外源蛋白时信号肽的选择方法及应用 | |
| CN102659928A (zh) | 一种人工合成的信号肽及其应用 | |
| Merkaš et al. | The MFα signal sequence in yeast-based protein secretion: challenges and innovations’ | |
| EP0225860A2 (en) | A method to export gene products to the growth medium of Gram negative bacteria | |
| JP7242829B2 (ja) | 新規細菌ｌｐｐ突然変異体及び組換えタンパク質の分泌産生のためのその使用 | |
| CN118546941A (zh) | 一种rspo1蛋白的表达载体及其应用 | |
| HK40006980A (en) | Novel signal sequences to improve protein expression and secretion of recombinant enzymes and other proteins | |
| He et al. | Nonclassical secretion of human catalase on the surface of CHO cells is more efficient than classical secretion | |
| CN103483423A (zh) | 一种人工合成的信号肽及其应用 | |
| HK1189913B (en) | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | |
| HK1189913A (en) | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins | |
| Rondahl et al. | Fusions to the 5′ end of a gene encoding a two-domain analogue of staphylococcal protein A | |
| CN114829578B (zh) | 用于在发酵方法中释放重组蛋白的细菌菌株 | |
| TWI754872B (zh) | 用於製備蛋白的嵌合型訊息肽 | |
| KR101692966B1 (ko) | 세포벽 결함 효모 변이주를 이용한 재조합 단백질 분비능이 향상된 효모 균주의 스크리닝 방법 | |
| US20130059335A1 (en) | Use of a genetically modified cell line expressing functional asialoglycoprotein receptor in the production of sialylated glycoproteins | |
| CN104059128A (zh) | 一种人工合成的信号肽及其应用 | |
| CN102659927A (zh) | 一种人工合成的信号肽及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: new jersey Applicant after: Amicus Therapeutics Inc. Address before: American Pennsylvania Applicant before: Callidus Biopharma Inc |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CALLIDUS BIOPHARMA INC. TO: AMICUS THERAPEUTICS INC. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |